Keytruda (pembrolizumab)

pCPA File Number: 22864
Negotiation Status:
Concluded with an LOI
Indication(s):
Neoadjuvant-adjuvant treatment of
adult patients with stage III or stage IV melanoma
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PX0346-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: